Table 1.
Sociodemographic and Clinical Characteristics of Patients, SPHMMC, Addis Ababa, 2020
| Total | Male N (%) | Female N (%) | |
|---|---|---|---|
| Age group | |||
| ≤39 years | 98 (30.6%) | 13 (12.9%) | 85 (38.8%) |
| 40–59 years | 191 (59.7%) | 74 (73.3%) | 117 (53.4%) |
| ≥60 | 31 (9.7%) | 14 (13.9%) | 17 (7.8%) |
| Missing | 13 (3.9%) | ||
| Marital status | |||
| Never married | 25 (8%) | 13 (13.4%) | 12 (5.6%) |
| Married | 140 (44.7%) | 64 (66%) | 76 (35.2%) |
| Separated/divorced | 67 (21.4%) | 11 (11.4%) | 56 (25.9%) |
| Widowed | 81 (25.9%) | 9 (9.3%) | 72 (33.3%) |
| Missing | 20 (6%) | ||
| Education | |||
| No education | 54 (16.4%) | 10 (9.8%) | 44 (19.3%) |
| Primary school | 138 (41.8%) | 41 (40.2%) | 97 (42.5%) |
| Secondary school | 98 (29.7%) | 32 (31.3%) | 66 (29%) |
| College or higher | 40 (12.1%) | 19 (18.7%) | 21 (9.2%) |
| Missing | 3 (0.9%) | ||
| CD4 count (cells/mm3) | |||
| < 200 | 18 (6.5%) | 7 (8.3%) | 11 (5.7%) |
| 200–349 | 43 (15.5%) | 9 (10.7%) | 34 (17.6%) |
| 350–499 | 61 (22%) | 21 (25%) | 40 (20.7%) |
| ≥ 500 | 155 (56%) | 47 (56%) | 108 (56%) |
| Missing | 56 (16.8%) | ||
| Viral load (copies/mL) | |||
| < 50 | 202 (80.8%) | 64 (84.2%) | 138 (79.3%) |
| ≥ 50 | 48 (19.2%) | 12 (15.8%) | 36 (20.7%) |
| Missing | 83 (24.9%) | ||
| Current regimen | |||
| TDF/3TC/EFV OR NVP | 228 (69.3%) | 68 (67.3%) | 160 (70.2%) |
| AZT/3TC/EFV OR NVP | 69 (21%) | 22 (21.8%) | 47 (20.7%) |
| TDF OR AZT/3TC/LPV/R | 6 (1.8%) | 4 (4%) | 2 (0.9%) |
| Other | 26 (7.9%) | 7 (6.9%) | 19 (8.3%) |
| Missing | 4 (1.2%) | ||
| Mean years since diagnosis | 10.58 ± 3.9 | 11.18 ± 3.8 | 10.3 ± 3.8 |
| Mean years on ART | 10.07 ± 3.9 | 10.86 ± 3.8 | 9.69 ± 3.86 |
Abbreviations: 3TC, Lamivudine; ART, Anti-Retroviral Treatment; AZT, Zidovudine; EFV, Efavirenz; LPV, Lopinavir/ritonavir; NVP, Nevirapine; TDF, Tenofovir Disoproxil Fumarate.